[PRNewswire] Alamar Biosciences partners with Abcam to drive understanding of
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Dr. Yuling Luo, Founder & CEO of Alamar, commented: "Alamar is working to enable the early detection of cancer and other diseases by simultaneous measurement of hundreds to thousands of targets, even those present in minute amounts. We are very happy to partner with Abcam to access their extensive portfolio of recombinant monoclonal antibody pairs, which will accelerate our ability to bring our proteomic discovery tools to researchers."
"We are excited to be partnering with Alamar as they develop an automated proteomics platform that has the potential to offer unprecedented combination of sensitivity, plex-level and dynamic range," commented Dr Emma Sceats, SVP Sales, Service and Business Development at Abcam. "The NULISA technology platform will provide an important tool for life science research, pharmaceutical development and diagnostics, enhancing understanding of the circulating proteome and supporting low abundance biomarker discovery. Such capability will be critical for the discovery and measurement of many proteins in human plasma and other samples that are currently undetectable."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
the human proteome
-- Alamar selects Abcam as a key provider of antibody content for its propriety NULISA technology platform
(FREMONT, Calif. and CAMBRIDGE, England, Jan. 4, 2022 PRNewswire=연합뉴스) Alamar Biosciences [https://alamarbio.com/ ] (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam [https://www.abcamplc.com/ ] (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of the human proteome.
The field of proteomic analysis is in the spotlight. Its advance not only enhances the understanding of fundamental biology, but also sheds light on the status of human health and disease. A deeper understanding of the proteome is set to play a crucial role in enabling the next wave of innovations in research, diagnostics and therapeutics. Powering this effort requires new technology platforms that are able to address the two essential goals in proteomic analysis, namely the ability to go as deeply as possible to detect very low abundance proteins and the ability to profile thousands of proteins in a single sample.
Dr. Yuling Luo, Founder & CEO of Alamar, commented: "Alamar is working to enable the early detection of cancer and other diseases by simultaneous measurement of hundreds to thousands of targets, even those present in minute amounts. We are very happy to partner with Abcam to access their extensive portfolio of recombinant monoclonal antibody pairs, which will accelerate our ability to bring our proteomic discovery tools to researchers."
"We are excited to be partnering with Alamar as they develop an automated proteomics platform that has the potential to offer unprecedented combination of sensitivity, plex-level and dynamic range," commented Dr Emma Sceats, SVP Sales, Service and Business Development at Abcam. "The NULISA technology platform will provide an important tool for life science research, pharmaceutical development and diagnostics, enhancing understanding of the circulating proteome and supporting low abundance biomarker discovery. Such capability will be critical for the discovery and measurement of many proteins in human plasma and other samples that are currently undetectable."
Abcam's portfolio of over 1,300 fit-for-purpose recombinant antibody pairs is actively curated to ensure that it is representative of the key disease areas of interest. Designed to enhance biomarker discovery and support deeper understanding of the circulating proteome, the portfolio has been pre-validated specifically for multiplex applications.
About Alamar Biosciences
Alamar Biosciences is a privately held life sciences company with a mission to transform the field of proteomics to enable the early detection of cancer and other diseases. The company's two proprietary technology platforms, NULISA™ and Attobody™, work seamlessly with the latest advances in genomics to achieve single-digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. The Attobodies have picomolar affinity and built-in high specificity and have the potential to expand antibody therapeutics to many targets intractable with conventional antibodies. For more information, please visit www.alamarbio.com.
About Abcam plc
As a global life sciences company, Abcam identifies, develops, and distributes high-quality biological reagents and tools that are crucial to research, drug discovery and diagnostics. Working across the industry, the Company supports life scientists to achieve their mission, faster.
Abcam partners with life sciences organizations to co-create novel binders for use in drug discovery, in vitro diagnostics and therapeutics, driven by the Company's proprietary discovery platforms and world-leading antibody expertise.
By constantly innovating its binders and assays, Abcam is helping advance the global understanding of biology and causes of disease, which enables new treatments and improved health. The Company's pioneering data-sharing approach gives scientists increased confidence in their results by providing validation, user comments and peer-reviewed citations for its 90,000 products.
With 14 sites globally, many of Abcam's over 1,600-strong team are located in the world's leading life sciences research hubs, complementing a global network of service and support.
To find out more, please visit www.abcam.com and corporate.abcam.com.
Logo: https://mma.prnewswire.com/media/1712644/Abcam_and_Alamar_Biosciences_Logo.jpg
Abcam and Alamar Biosciences Logo
Source: Abcam
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
출처 : PRNewswire 보도자료
Copyright © 연합뉴스 보도자료. 무단전재 및 재배포 금지.
- 민수용 도시가스요금 6.8% 인상…4인 가구 기준 월 3천770원↑(종합) | 연합뉴스
- 7월 국회 파행 불가피…방송법·채상병특검 재표결 '뇌관' | 연합뉴스
- 尹, 3년 연속 나토 정상회의 참석…북러 밀착에 강력한 메시지(종합) | 연합뉴스
- '대국민사과' 김여사 문자 무시했나…韓 "사적방식 논의 부적절" | 연합뉴스
- "대의민주주의 파괴 행위"…이재명 습격범에 징역 15년 선고(종합) | 연합뉴스
- 효성 차남 조현문 "상속재산 전액 사회환원…경영권 관심없어"(종합2보) | 연합뉴스
- 경찰 "시청역 사고 발생 전 CCTV에 부부 다투는 모습 없다" | 연합뉴스
- 박정훈측 "대통령실이 항명 수사 개입"…군검찰 "외부관여 없어" | 연합뉴스
- "다시 메모리의 시간"…삼성전자 2분기 영업익 10.4조 '깜짝실적'(종합) | 연합뉴스
- '총선 압승' 英노동당 스타머, 승리 선언…"변화는 지금 시작"(종합2보) | 연합뉴스